Rating: Cautiously Bullish (Earnings massively exceeded expectations + SCA structural improvement, odds improved but risks remain high) Target Price Range: $800–$1,200 (Base Case) Current Price: $937.00 (Close, 2026-07-13) Margin of Safety: −14.6% (Base fair value low of $800 vs current price $937) Time Horizon: 6 months
| Dimension | Previous (2026-06-17) | Current (2026-07-14) | Catalyst |
|---|---|---|---|
| Rating | Neutral | Cautiously Bullish | Upgrade. Q3 revenue beat guidance by 24% + SCA $22B deposit commitment significantly raises earnings base; current price enters lower part of base case range, odds improved |
| Confidence | 0.70 | 0.65 | Slight decrease: New litigation risk + Red team highlights SCA double-edged sword (floor price implies ceiling price) |
| Target Price Range | $750–$1,100 | $800–$1,200 | Upward revision of ~$50: SCA $22B deposit commitment structurally improves earnings visibility; normalized EPS raised from $15 to $25–35 |
| Valuation Stance | Overvalued | Overvalued | Maintained. Current price $937 still above base fair value median of $1,000; PE(TTM) dropped from 47.8x to 21.3x due to earnings surge, not valuation reversion |
| Current Price | $1,020.76 | $937.00 | Stock fell 8.2%; margin of safety improved from −27% to −14.6% |
FY2026 Q3 (ended 2026-05-28) revenue of $41.46B substantially exceeded guidance of $33.5B (+24%). GAAP gross margin of 84.6% and Non-GAAP EPS of $25.11 were both all-time highs. Q4 guidance: revenue $50B, gross margin ~86%, Non-GAAP EPS $31.00, setting new records. SCA Strategic Customer Agreements achieved a breakthrough—customer deposit commitments of $22B ($18B cash), take-or-pay structure, floor price corresponding to gross margin "far above any historical cycle peak", fundamentally improving earnings visibility.
However, ASP growth has slowed from QoQ +58-63% in Q2 to +13-18% in Q3 (DRAM contract prices). Gross margin sequential improvement decelerated from +6.1pp to +1.4pp. A DRAM price-fixing class action lawsuit (118-page complaint) filed on 2026-06-30 constitutes a significant new risk. CEO Mehrotra sold another ~$46M on 6/30, bringing FY2026 cumulative sales to ~$104M, the highest since 2010.
Current price $937 (−8.2% from thesis date), PE(TTM) 21.3x (down sharply from 47.8x at thesis date). Post-Q4 forward PE approximately 12.8x. Valuation has improved significantly vs last month, but the low PE is driven by peak earnings—if EPS mean-reverts to normalized $25–35, the corresponding PE of 27–37x remains in the high historical range.
Judgment: The earnings base has been significantly raised (SCA is a genuine structural improvement). Odds have improved from slightly unfavorable to slightly favorable (probability-weighted expected return +15.4%). Upgraded to Cautiously Bullish, but risks remain high—litigation progress + ASP growth deceleration are key constraints. Focus on Q4 actual vs $50B guidance and litigation developments.
Key Evidence:
Micron FY2026 Q3 Earnings Release (8-K EX-99.1, 2026-06-24): Revenue $41,456M (Q2 $23,860M, QoQ +74%); GAAP gross margin 84.6% (Q2 74.4%, +10.2pp); GAAP net income $28,243M ($24.67 diluted EPS); Non-GAAP net income $28,857M ($25.11 diluted EPS). Q4 guidance: revenue $50.0B ± $1.0B, gross margin ~86%, Non-GAAP EPS $31.00 ± $1.00.
Micron FY2026 Q3 10-Q (2026-06-25), MD&A and Liquidity: SCA customer deposit commitments of $22B ($18B cash); take-or-pay contracts include floor and ceiling prices; floor gross margin "far above any historical cycle peak". CEO Sanjay Mehrotra: "These agreements accelerate the transformation of our business model and will significantly enhance the durability and predictability of our financial performance."
TrendForce 2026-07-09 DRAM Contract Price Report: Q3 2026 DRAM contract prices QoQ +13-18%, a clear deceleration from Q2's +58-63%. LTA locked prices also limit supplier pricing power.
Q3 actual results significantly above guidance indicate management guidance was conservative and demand continues to exceed expectations. But ASP growth deceleration cannot be ignored—gross margin sequential improvement narrowed from +6.1pp in Q2 to +1.4pp in Q3, and Q4 guidance implies only another +1.4pp. The SCA improvement in earnings visibility is real, but the ceiling price clause means that in a super cycle, SCA also limits pricing upside—a double-edged sword.
Key Evidence:
Micron FY2026 Q3 Earnings Release (2026-06-24), Product Highlights: HBM4 (based on 1β DRAM) is shipping in volume; qualification samples received from multiple end customers; HBM4E (based on 1γ DRAM) under development, expected to enter production in CY2027.
Counterpoint Research Q1 2026 / Silicon Analysts 2026-07-10: SK hynix HBM share 56.4%, Micron ~18-22%, Samsung ~17-20%. Micron data center gross margin 87%, but TrendForce notes that DDR5 64GB RDIMM wafer profit has surpassed HBM—"More HBM ≠ More profit".
Reuters 2026-01-02: Samsung HBM4 received NVIDIA qualification and entered volume production in February 2026, earning customer comments "Samsung is back", diluting Micron's HBM scarcity.
Micron FY2026 Q3 10-Q Note 14: Remaining performance obligations ~$5B, about one-third to be recognized as revenue in the next 12 months; contracts include fixed prices, min/max price ranges, and market-based pricing structures.
HBM4 volume production progress is in line with expectations, but the competitive landscape has not improved as the thesis expected—Samsung HBM4 is fully back, and SK hynix's share advantage has expanded to 3x Micron. The SCA contract's "floor gross margin far above historical peaks" is a genuine structural improvement, but the ceiling price clause limits upside flexibility. Micron's HBM share has slipped from 21% to ~18-20%, a trend to watch.
Key Evidence:
Counterpoint Research Q1 2026: DRAM CR3 ~92% (Samsung 38%, SK hynix 29%, Micron 22%, CXMT 8%).
DRAM Price-Fixing Class Action (NDCA Case 3:26-cv-6345, filed 2026-06-25): 118-page complaint alleges the three majors have engaged in "coordinated conduct" since 2022—concurrent production cuts, coordinated shift to HBM, unified exit from DDR3/DDR4, refusal to expand capacity—inflating DRAM prices by 697%. Historical precedent: In 2005 Samsung/SK hynix pleaded guilty and paid fines in a similar lawsuit. If the motion to dismiss survives, discovery will force disclosure of internal communications.
Micron FY2026 Q3 10-Q (2026-06-25), Liquidity: FY2026 CapEx ~$27B (net); Boise first fab expected to start production mid-2027, second fab starts construction 2026 with production late 2028; Clay NY first fab 2030+ sourcing.
SK hynix ADR Listing (2026-07-10): Up 13.1% on Nasdaq first day, raised ~$26.5B, market cap $1.2T surpassing Micron's $1.1T. Proceeds directly fund Yongin capacity expansion, with new supply coming online 2027-2028.
The price-fixing lawsuit is the most important new risk in this update. If the lawsuit survives the motion to dismiss and enters discovery, historical precedent is unfavorable for the three majors. The oligopoly structure itself is a natural target for antitrust risk—"CR3 ~92% provides pricing power" is also the biggest source of legal risk. SK hynix's ADR listing provides US investors direct exposure to the HBM leader, potentially diverting AI memory capital that previously flowed to Micron.
Key Evidence:
This report's calculation (based on 2026-07-13 close $937 + Q3 10-Q): Market cap = $937 × 1,129M shares ≈ approximately $1.06 trillion. PE(TTM) = $937 / $44.08 = 21.3x (TTM GAAP NI ~$50.5B). PB = $937 / $89.24 = 10.5x. Net cash $24.4B ($21.61/share), only 2.3% of total market cap.
Post-Q4 forward PE: FY2026E Non-GAAP NI ~$84B → forward PE = $937 / ($84B/1,149M) ≈ 12.8x. But this is based on peak earnings with gross margin ~85%.
Normalized check: SCA pushes mid-cycle EPS from historical ~$5 to ~$25–35 (SCA floor protection + HBM structural demand), corresponding to normalized PE of 27–37x—still well above historical median of 10–15x. 24/7 Wall St. (2026-06-24) notes: "Pricing at 53x trailing earnings in a cyclical industry, a forward PE of 11x only holds if peak margins never normalize."
S&P Global 2026-06 sell-side consensus: FY27E EPS $112 (PE 8.4x), below some optimistic estimates of $150 (PE 6.2x). Both assume a sustained super cycle and are not comparable after normalization.
StockAnalysis.com 2026-07-13: 45 analysts average target ~$1,486 (31 Strong Buy / 9 Buy / 5 Hold / 0 Sell). TD Cowen maintains Buy, target $1,600 (most bullish). Michael Burry disclosed short @$1,051.87.
Using peak earnings to calculate forward PE (12.8x or even 6.3x) is the most common trap in semiconductor cyclicals—in 2018, Micron's PE fell to 4x just before the stock subsequently halved. At the same time, SCA has indeed raised the earnings floor from ~$5 to ~$25–35, making Micron's "normalized" not comparable to historical averages. The market's pricing of Micron is a tug-of-war between two narratives: "structural transformation" vs "another cyclical peak."
Key Evidence:
Micron FY2026 Q3 10-Q (2026-06-25), Liquidity: FY2026 CapEx ~$27B (net of government incentives). Construction in progress rose from $5.52B at end of FY2025 to $10.94B.
SEC Form 4 (2026-06-30): CEO Sanjay Mehrotra sold ~40,000 shares at ~$1,150 average price on 6/30 (~$46M), executed under a 10b5-1 plan. Combined with May sales of ~$58M, FY2026 cumulative ~$104M. Director Steven Gomo, CBO, EVP of Sales, and Chief People Officer also net sellers simultaneously—24/7 Wall St. counts 102 insider transactions, all net sells.
Micron FY2026 Q3 10-Q, SCA Deposits: $22B customer deposit commitments ($18B cash). But the timeline for receipt and usage restrictions are not detailed. CapEx coverage = $18B / $27B = 66.7%—"partially offset" is accurate, but FY2027 CapEx is expected to increase substantially again (construction +~$10B), and FCF will deteriorate quickly.
Micron 2026-07-09 Press Release (Clay NY Fab): First concrete pour advanced by one quarter; US investment commitment raised to $250 billion—long-term positive but near-term CapEx burden increases.
The magnitude of CEO and senior management's synchronized selling is the highest since 2010—although executed under pre-arranged 10b5-1 plans, the breadth and timing are worth noting. SCA deposits of $18B cash cover 66.7% of FY2026 CapEx, but with FY2027 CapEx expected to rise further, coverage will drop significantly. Burry notes "Micron experiences capital impairment on average every three quarters, with free cash flow negative for nearly half of the time"—a pattern worth heeding during this period of sharply rising CapEx.
| Metric | FY2023 | FY2024 | FY2025 | FY2026 Q3 (Single Quarter) | 9 Months FY2026 |
|---|---|---|---|---|---|
| Revenue (in billions of USD) | 15.54 | 25.11 | 37.38 | 41.46 | 78.96 |
| Revenue YoY | −49.5% | +61.5% | +48.9% | +346% | +203% |
| GAAP Net Income (in billions of USD) | −5.833 | 0.778 | 8.539 | 28.243 | 47.268 |
| Non-GAAP Net Income (in billions of USD) | — | — | ~9.511 | 28.857 | ~48.357 |
| Gross Margin | −9.1% | 22.4% | 39.8% | 84.6% | 76.6% |
| Net Margin | −37.5% | 3.1% | 22.8% | 68.1% | 59.9% |
| Operating Cash Flow (in billions of USD) | 1.559 | 8.507 | 17.525 | 25.388 | 45.702 |
| Free Cash Flow (in billions of USD)¹ | −6.117 | 0.121 | 1.668 | 18.304 | 26.100 |
| Cash & Equivalents (in billions of USD)² | — | — | 11.936 | 34.234 | 34.234 |
| Interest-Bearing Debt (in billions of USD)² | — | — | 14.577 | 5.722 | 5.722 |
| Net Cash (in billions of USD)² | — | — | −2.641 | 28.512 | 28.512 |
| Debt-to-Asset Ratio | — | — | 34.6% | 24.9% | 24.9% |
¹ Q3 uses company-reported Adjusted FCF = OCF − Net CapEx ($25,388M − $7,084M = $18,304M). 9-month FCF = OCF $45,702M − PPE expenditures $19,602M = $26,100M. ² Cash & Equivalents = Cash + Short-term investments + Long-term marketable securities + Restricted cash. End of Q3 (2026-05-28): $24,995M + $1,027M + $4,106M + $27M = $30,155M. Net Cash = $30,155M − $5,722M total debt + $4,106M long-term marketable securities (already included) ≈ $24,433M ≈ $24.4 billion.
FY2026 Q3 (reporting period ended May 28, 2026) posted revenue of $41.46B, gross margin of 84.6%, and GAAP net income of $28.24B, all exceeding guidance. This marks Micron's fifth consecutive record quarter.
Q3 vs Guidance Comparison:
| Metric | Q3 Actual | Q2 Guidance (3/18) | Beat |
|---|---|---|---|
| Revenue | $41.46B | $33.5B ± $0.75B | +24% (above high end) |
| GAAP Gross Margin | 84.6% | ~81% | +3.6pp |
| Non-GAAP EPS | $25.11 | $19.15 ± $0.40 | +31% |
DRAM revenue $31.33B (+343% YoY), ASP up in the low 260% range + bit shipments up low-20% . NAND revenue $9.94B (+361% YoY), ASP up in the mid 310% range.
Q4 Guidance (ends August 2026): Revenue $50.0B ± $1.0B, Gross Margin ~86%, Non-GAAP EPS $31.00 ± $1.00. Implied FY2026 full-year revenue ~$129B, Non-GAAP NI ~$84B (EPS ~$73).
SCA Breakthrough: Q3 10-Q disclosed SCA terms for the first time in detail — take-or-pay multi-year contracts, most with minimum/maximum pricing ranges, the largest contract ceiling approximately equal to the market price in Q2 2026, floor price implying gross margin "well above any historical cycle peak". Customer deposit commitments from signed contracts total $22B ($18B in cash). This is a true structural innovation — unprecedented revenue visibility in the storage industry.
However: Q4 guidance of $50B revenue and ~86% gross margin means gross margin improves only +1.4pp sequentially — deceleration is a fact. Moreover, after the Q3 earnings release, the stock fell on the day — a clear "buy the rumor, sell the news" pattern.
Maintains prior assessment: Micron is a capital-intensive vertical IDM, with core products DRAM (76% of Q3 revenue) and NAND (24%). However, Q3 saw a fundamental change — SCA (Strategic Customer Agreements) shift Micron's revenue model from "fully driven by spot/contract market prices" to "partially driven by long-term locked-price contracts".
| Metric | FY2023 | FY2024 | FY2025 | FY2026 First 9 Months |
|---|---|---|---|---|
| OCF / GAAP NI | −0.27x | 10.93x | 2.05x | 0.97x |
| FCF / GAAP NI | — | — | 0.20x | 0.55x |
FY2026 first 9 months OCF/NI = 0.97x — close to but slightly below 1.0x, mainly due to surge in receivables of $19.95B consuming cash. FCF/NI = 0.55x improved significantly from FY2025's 0.20x (revenue growth far exceeds CapEx), but with FY2027 CapEx increasing again, FCF will come under pressure again.
FY2026 annualized ROIC estimate: NOPAT (first 9 months annualized) ≈ $74.1B / Invested Capital ≈ $131.9B ≈ 56%. But this relies on peak profitability with 77% gross margin. Long-term sustainable ROIC depends on whether SCA can stabilize mid-cycle ROIC above 15%+ — management claims SCA floor gross margin is "well above any historical cycle peak" (i.e., FY2018 ~60%), if true, mid-cycle ROIC could be maintained at 20-30%, constituting a true moat.
| Metric | FY2025 | FY2026 First 9 Months (Annualized) |
|---|---|---|
| CapEx / Depreciation | 1.90x | 2.86x |
CapEx/Depreciation from first 9 months annualized $26.1B / $9.1B ≈ 2.86x (FY2025: 1.90x), persistently well above the 1.0x maintenance threshold. SCA deposits of $18B in cash can partially cover but are not sustainable — FY2027 CapEx expected to increase by ~$10B (construction), then CapEx/Depreciation could exceed 3.0x.
| Metric | Value | Comment |
|---|---|---|
| Stock Price | $937.00 (close, July 13, 2026) | — |
| Market Cap | ~$1.06T (basic) / ~$1.07T (diluted) | — |
| PE(TTM) | 21.3x | Earnings not representative (TTM NI ~$50.5B is cycle peak) |
| Post-Q4 Forward PE | ~12.8x | Based on FY2026E Non-GAAP EPS ~$73 |
| FY27E PE (S&P Global $112) | 8.4x | Still assumes super-cycle persists |
| PB | 10.5x | Far above peers SK hynix ~1.8x, Samsung ~1.2x |
| PS(TTM) | 11.7x | — |
| Net Cash/Share | $21.61 | Only 2.3% of total market cap |
Peer Comparison Table:
| Company | PE(TTM) | PB | Revenue Growth | ROE | Key Difference |
|---|---|---|---|---|---|
| Micron Technology | 21.3x | 10.5x | +346% Q3 | 32.6% | DRAM #3/HBM #2, SCA lock-in innovation |
| SK hynix | N/A (ADR newly listed) | ~1.8x | +47% (FY2025) | ~23% | HBM #1 (~54%), ADR mkt cap $1.2T |
| Samsung Electronics | N/A | ~1.2x | — | ~8-10% | DRAM #1/NAND #1/HBM #3, memory+foundry conglomerate |
| Western Digital | ~6.8x | — | — | 37.7% | NAND+HDD only, limited comparability |
Current price $937 implies the market believes: Sustainable (normalized) EPS is about $76/share = ($937 − $21.6 net cash) / 12x mid-cycle PE. For reference: ① Historical median ~$5; ② After SCA structural adjustment ~$25-35; ③ TTM $44 (super-cycle peak); ④ Sell-side FY26E $73 (peak year); ⑤ Sell-side FY27E $112–150.
Current price implies $76/share perpetual earnings, which is 2.2-3.0x the SCA-adjusted mid-cycle $25-35. The market is pricing in "super-cycle forever."
| Value Layer | Per Share Value | % of Current Price |
|---|---|---|
| Asset Value (BV) | $89 | 9.5% |
| EPV Zero-Growth | ~$226 | 24.1% |
| Growth Option | ~$711 | 75.9% |
Normalized EPS raised to $20–25 (SCA floor + HBM structural demand, up from prior $15), WACC 11%, net cash $21.61/share. EPV share rises from 13.9% to 21.7% — SCA indeed lifts zero-growth value, but growth option still accounts for ~76% of current price.
| Scenario | Probability | Fair Value | Key Driver | vs Current Price |
|---|---|---|---|---|
| 🐻 Bear | 25% | $400–$550 | Price-fixing lawsuit lost / DRAM ASP down 50%+ from peak. EPS falls to $15-25, 12-16x PE. SCA floor provides partial protection | −41% to −57% |
| 📊 Base | 50% | $800–$1,200 | AI demand persists through FY2028, SCA lock-in executes, commodity DRAM ASP mild decline 15-25%. FY2027 Non-GAAP EPS $55-80, 13-18x PE | −15% to +28% |
| 🐂 Bull | 25% | $1,500–$2,200 | AI super-cycle extends to 2029, HBM share rises to 25%+, litigation dismissed. FY2027 EPS $100-140, 15-18x PE | +60% to +135% |
Odds Distribution: Current price $937 sits in the lower part of the base scenario. Bear case downside 41-57% (25% probability), Base −15% to +28% (50% probability), Bull upside 60-135% (25% probability).
Base Scenario Ramp Calculation: HBM revenue from FY2026E ~$40-50B ramps to FY2028 ~$70-90B (HBM TAM grows to ~$100B, Micron share ~20-25%); commodity DRAM revenue from FY2026E ~$50-60B declines 15-25% in FY2027-2028; exit year (FY2028) Non-GAAP EPS $50-65, 13-18x PE. Exit multiple anchor: vs SK hynix current ~1.8x PB + Samsung ~1.2x PB; Micron's SCA lock-in justifies 1.5-2.0x mid-cycle PB valuation.
Bear case $400-550 covers the most pessimistic published forecast on the market — 24/7 Wall St.'s SELL rating implies valuation ~$539, and Michael Burry's short thesis implying return to historical median ROIC (~4%) is also within range.
| FY2026E Revenue | FY2026E Non-GAAP EPS | FY2027E Revenue | FY2027E Non-GAAP EPS | |
|---|---|---|---|---|
| This Report | $127–131B | $71–75 | $180–230B | $55–80 |
| Management Guidance | Q4 $50B ± $1B | Q4 $31.00 ± $1.00 | Not disclosed | Not disclosed |
| Sell-Side Consensus | — | ~$73 (StockAnalysis) | ~$234B | $112 (S&P Global) – $150 (overstated) |
Key assumptions (FY2027): HBM shipments more than double (HBM4 production ramp + HBM4E sampling), DRAM bit growth ~20-30%, NAND bit ~15-20%. HBM4 ASP premium +20-40%, commodity DRAM/NAND ASP declines 15-25% from FY2026 peak. Non-GAAP gross margin 65-75% (commodity decline partly offset by increasing HBM share). CapEx ~$25-30B.
Judgment: Overvalued, but odds have improved to slightly favorable. Current price $937 sits in the lower part of the base scenario, margin of safety −14.6%. The improvement in earnings base (SCA + HBM structural demand) is real — normalized EPS raised from prior $15 to $25-35 — but the $76/share perpetual earnings implied by current price is still 2.2-3.0x the normalized level. Post-Q4 forward PE of 12.8x appears cheap, but is based on peak earnings with ~85% gross margin. However, the earnings visibility from SCA's $22B deposit commitments was underestimated in the prior thesis, and the current odds (probability-weighted expected return +15.4%) have improved significantly from one month ago (+2.3%). Below $800 (corresponding to base fair value low end) provides better safety.
Micron's FY2026 Q3 delivered the strongest quarter in history with $41.5B revenue (+24% above guidance), and Q4 guidance of $50B sets another record. The SCA strategic customer agreements ($22B deposit commitments, take-or-pay, floor gross margin well above historical peak) represent an unprecedented structural innovation in the storage industry, fundamentally improving earnings visibility.
However, three new risks offset the earnings improvement: ① The DRAM price-fixing class action lawsuit (118-page complaint) if it survives the motion to dismiss, will exert persistent pressure on valuation; ② ASP growth decelerated from +58-63% QoQ to +13-18%, gross margin improvement also slowed — the super-cycle's marginal momentum is weakening; ③ CEO and senior management simultaneously executed large-scale selling (FY2026 cumulative ~$104M, highest since 2010).
Current price $937 is down 8.2% from thesis initiation date, PE(TTM) dropped from 47.8x to 21.3x — but the low PE is driven by peak earnings, still historically elevated after normalization. Upgraded to cautiously bullish. Below $800 is a better entry window, but maintain position control until litigation developments are clearer.
Key Tracking Metrics:
| Catalyst | Expected Timing | Verification Metric |
|---|---|---|
| FY2026 Q4 Actual Results | Sep 2026 | Actual revenue vs $50B guidance; FY2027 preliminary outlook |
| DRAM Price-Fixing Lawsuit | 2026-H2 | Court ruling on motion to dismiss |
| DRAM Contract Price Q4 Negotiations | Aug 2026 | ASP QoQ further deceleration (<10% is red flag) |
| HBM4 48GB 16-Hi NVIDIA Qualification | 2026-Q4 | NVIDIA official announcement; Micron share change |
| CEO/Senior Mgmt Subsequent Selling | Ongoing | Form 4 filing frequency and size |
This report is based on public information and proprietary model estimates and does not constitute investment advice. Valuation relies on multiple assumptions (normalized EPS, WACC, scenario probabilities); changes in assumptions would lead to significant changes in conclusions. Release date: July 14, 2026.